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 ABSTRACT 
 The dry period is a critical time in the lactation cycle, 
being the optimum time to cure existing intramammary 
infection (IMI) as well as encompassing the periods of 
highest susceptibility to new infection. Currently, IMI 
in the dry period is controlled with antibiotic dry cow 
therapy. The aim of this randomized control trial was 
to investigate different dry cow therapy regimens by 
stratifying cows by likely infection status at drying off in 
herds with low somatic cell count (SCC; bulk milk SCC 
<250,000 cells/mL) in southwest England. All quarters 
in 890 cows were recruited. The recruited cows were 
categorized as either infected or uninfected on the basis 
of SCC and clinical mastitis history. Ipsilateral quarters 
within each cow were randomly allocated to receive 1 of 
4 different treatment regimens according to their infec-
tion category. Quarters in high-SCC infected cows were 
allocated to receive antibiotic dry cow therapy either 
alone or in combination with an internal teat sealant; 
quarters in low-SCC uninfected cows were allocated to 
receive teat sealant either alone or in combination with 
antibiotic dry cow therapy. All quarters were sampled 
for bacteriology at drying off and again within 10 d 
post-calving. Quarters were subsequently monitored 
for clinical mastitis for the first 100 d of lactation. 
The mass of residual sealant was assessed immediately 
post-calving to allow assessment of the association of 
sealant retention with treatment efficacy. Models were 
constructed to assess the efficacy of the different regi-
mens in preventing IMI. Apparent cure rates of existing 
IMI with major pathogens were consistently >90% in 
quarters receiving antibiotic. Combination treatment of 
high-SCC infected cows resulted in an increased likeli-
hood of being pathogen free post-calving (odds ratio = 
1.40; 95% credibility interval = 1.03–1.90). The benefits 
of combination treatment of low-SCC uninfected cows 
were less clear. With respect to clinical mastitis, combi-
nation treatment of high-SCC infected cows resulted in 
a decreased likelihood of developing clinical mastitis in 
the first 100 d of the subsequent lactation (odds ratio = 
0.68; 95% credibility interval = 0.48–0.98). The reten-
tion of the internal sealant was adversely affected by its 
use in combination with antibiotic dry cow therapy. 
 Key words:   dry cow therapy ,  cephalonium ,  intra-
mammary infection ,  teat sealant 
 INTRODUCTION 
 The rigorous implementation of mastitis control plans 
in recent years resulted in a dramatic change in both 
the incidence and etiology of bovine mastitis (Bradley, 
2002). Historically, these control programs were focused 
on contagious mastitis pathogens and the control of bulk 
milk SCC (BMSCC; Dodd et al., 1969), an important 
part of which was the recommendation to implement 
whole-herd antibiotic dry cow therapy (Smith et al., 
1967; Wilson et al., 1972). 
 The dry period is well acknowledged as being the 
optimal time to cure existing IMI (Wilson et al., 1972) 
as well as being a period of high risk for the acqui-
sition of new IMI (Smith et al., 1985; Oliver, 1988). 
Research investigated the importance of infections 
acquired during the dry period and demonstrated how 
these infections influence the rate of clinical mastitis in 
the subsequent lactation (Bradley and Green, 2000). 
Importantly, research highlighted the potential impor-
tance of the dry period in the epidemiology of both 
environmental and contagious mastitis pathogens, and 
that dry period interventions can influence both the 
incidence and etiology of such infections (Bradley and 
Green, 2001; Huxley et al., 2002); one such example is 
the ability to reduce the incidence of clinical mastitis 
in early lactation caused by Enterobacteriaceae through 
selecting therapy with extended activity against these 
pathogens (Bradley and Green, 2001). 
 The renewed interest in the role of the dry period in 
mastitis control, coupled with the unfortunate public 
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perception of prophylactic antibiotic use, led to an in-
terest in nonantibiotic approaches to control IMI. This 
interest focused on the prevention of new IMI in cows 
with low SCC that were uninfected at drying off (DO) 
and culminated in studies investigating the utility of 
internal teat sealants in the prevention of new IMI in 
the dry period (Woolford et al., 1998; Berry and Hil-
lerton, 2002a; Huxley et al., 2002). Once the efficacy 
had been demonstrated in low-SCC uninfected cows, an 
obvious extension was to combine the use of an internal 
teat sealant with antibiotic (combination treatment) in 
high-SCC infected cows, thereby combining the benefits 
of enhanced cure with antibiotics with the enhanced 
ability of sealants to prevent new IMI (Godden et al., 
2003; Newton et al., 2008).
However, despite evidence to the contrary (Woolford 
et al., 1998), an assumption was made that the clear 
benefits of combination treatment in high-SCC infected 
cows could be extrapolated to low-SCC uninfected cows 
and that there would be a clear advantage to the use 
of combination treatment in all cows regardless of in-
fection status at DO. However, this assumption is not 
currently sustained by scientific evidence.
Therefore, the primary aim of the research outlined 
was to investigate the efficacy of combination treatment 
in both cows that were infected and uninfected at DO 
in terms of reduction in IMI and incidence of clinical 
mastitis in the first 100 d of the subsequent lactation. A 
secondary aim was to assess the recovery of the internal 
teat sealant after calving and to determine whether this 
was affected by the use of the product in combination 
with an oil-based antibiotic dry cow therapy.
MATERIALS AND METHODS
Herd Selection
Six commercial dairy herds in southwest England 
(Somerset and Wiltshire) were enrolled. Herds were se-
lected on the basis of existing records and participation 
in an individual cow milk recording scheme (to allow 
collation of historic SCC data). No strict criteria were 
imposed pertaining to BMSCC or clinical mastitis in-
cidence, though herds typically had BMSCC <250,000 
cells/mL.
Cow Selection
Cows eligible for enrollment were in good health, had 
4 functional quarters free of significant teat lesions, 
and had monthly individual cow SCC recordings for at 
least the 3 mo previously. Cows enrolled did not have 
systemic or intramammary antibiotics or antiinflamma-
tory agents in the 30 d before the last milking and had 
an expected dry period length of at least 54 d.
Study Protocol
Enrollment.  Farms were visited weekly, and cows 
were enrolled to the study on the day of DO. At enroll-
ment, key cow details such as breed, parity, estimated 
milk yield, individual cow SCC history, treatment his-
tory, and estimated calving date were collected from 
farm records. Additional data such as the presence or 
absence of teat lesions were recorded at the time of 
recruitment. Prior to the final milking of the lactation 
and before treatment administration, each animal was 
identified and physically examined for suitability on the 
basis of the exclusion criteria. Duplicate milk samples 
were collected for bacteriological examination and a 
single sample for SCC evaluation was collected from 
each quarter of each eligible animal using a method 
described previously (Bradley and Green, 2000).
Treatment Allocation and Administration. At 
DO, cows were categorized as high-SCC infected or 
low-SCC uninfected using clinical mastitis and SCC 
history; cows with the last 3 monthly individual SCC 
<200,000 cells/mL and no clinical mastitis within that 
period were allocated to the uninfected group; all other 
animals (with complete records) were allocated to the 
infected group.
In the high-SCC infected group, within each cow, 
ipsilateral quarters were randomly allocated to receive 
either antibiotic alone (AB; 250 mg of cephalonium, 
Cepravin Dry Cow, Intervet Schering-Plough Animal 
Health, Milton Keynes, UK) or combination treatment 
(ABTS; 250 mg of cephalonium, Cepravin Dry Cow, 
Intervet Schering-Plough Animal Health; 65% bismuth 
subnitrate in a mineral oil base, OrbeSeal Pfizer Ani-
mal Health, Sandwich, UK). In the low-SCC uninfected 
group, within each cow, ipsilateral quarters were ran-
domly allocated to either teat sealant alone (TS) or 
combination treatment (TSAB). The quarter was the 
experimental unit, although subsequent multivariable 
analysis took into account the effect of clustering of 
quarters within cows.
At each trial site, within the high-SCC infected and 
low-SCC uninfected groups the combination treatment 
was allocated to the left or the right side of the udder in 
the first cow recruited; thereafter, treatments were allo-
cated on an alternate basis according to the order that 
cows were recruited. Importantly, this approach ensured 
a balanced allocation of treatments to each side of the 
udder within each trial site and that allocation was 
temporarily matched even when small numbers of cows 
were recruited at a site. This approach was necessary 
to address any potential proclivity caused by housing 
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design, cows lying on one side, and any temporal varia-
tion in challenge given that environmental pathogens 
were the most likely cause of infection in the dry period 
in the modern dairy herd.
Dry cow therapy was administered by a member of 
the study team following strict aseptic precautions. 
Where appropriate, antibiotic dry cow therapy was 
infused into the teat cistern of a quarter and massaged 
into the udder. The teat sealant was carefully instilled 
into the teat sinus either as a stand-alone treatment or 
following treatment with antibiotic dry cow therapy as 
appropriate. Following treatment administration, quar-
ters were dipped with a post-milking disinfectant and 
cows were confined to a loafing yard for at least 30 min 
before moving to new accommodations.
Dry Period Management. Following treatment 
and until calving, animals were subjected to the usual 
dry cow husbandry practices for the farm and were 
regularly observed by the owner, herdsperson, or other 
suitably qualified person. Any disease or concurrent 
treatments were recorded. All cases of clinical mastitis 
were recorded and sampled for bacteriological analy-
sis.
Teat Sealant Recovery at Calving. At calving, or 
as soon as practicable thereafter, farmers and herdsper-
sons assessed and recorded the presence or absence of 
residual TS in each of the quarters according to a stan-
dard operating procedure and following training; in the 
event that a quarter had been suckled, this was noted. 
The first 50 mL of secretion (including strict foremilk) 
was collected from all quarters, regardless of whether 
they originally received sealant, into a prelabeled tube 
(1 tube per quarter). Each tube was frozen on farm 
until collected and returned to the laboratory.
Post-Calving. Duplicate quarter milk samples were 
collected for bacteriological examination at the first 
weekly visit after each cow had calved. At the same 
time, a milk sample was taken from each quarter for 
enumeration of the quarter SCC. Samples collected 
more than 10 d after calving were excluded from the 
analysis of efficacy as measured by the cure and acqui-
sition of IMI during the dry period.
Clinical Mastitis Monitoring. Farm personnel, 
trained in detection and aseptic sampling of clinical 
mastitis, monitored cows for the presence of clinical 
mastitis throughout the study period and collected a 
pretreatment aseptic quarter milk sample when cases 
occurred. These samples were frozen on farm and stored 
until the next routine visit.
Laboratory Procedures
All milk samples collected were maintained at or 
below 8°C during transport to the laboratory for analy-
sis. Microbiological investigation and SCC were car-
ried out using the standard milk sample examination 
techniques, which exceeded the standard recommended 
by the International Dairy Federation (1981), Interna-
tional Standard 13366–1:1997 (E) and 13366–2:1997 
(G). A more complete description of these techniques 
is outlined below.
Ten microliters of secretion was inoculated onto sheep 
blood agar and Edward’s agar; 100 μL of secretion was 
inoculated onto MacConkey agar to enhance the detec-
tion of Enterobacteriaceae. Plates were incubated at 
37°C and read at 24, 48, and 72 h. Organisms were 
identified and quantified using standard laboratory 
techniques (Quinn et al., 1994; NMC, 1999). Escheri-
chia coli were identified by colony morphology, oxidase, 
and indole tests; other Enterobacteriaceae were identi-
fied using a microtube identification system (RapiD 20 
E, bioMérieux, Basingstoke, UK).
Somatic cell count was determined using the Fos-
somatic method (Delta CombiScope – Model FTIR 
400, Drachten, the Netherlands) according to the FIL 
International Dairy Federation 148 A: 95 norm (Inter-
national Dairy Federation, 1995).
Samples collected and frozen on farm were thawed 
prior to centrifugation at 3,000 × g for 5 min. Secretion 
was decanted, leaving the remnants of teat sealant and 
other solids in the base of the tube. Tubes were inverted 
and allowed to drain fully before weighing to establish 
the mass of retrieved solids (teat sealant).
Assessment of Efficacy
Isolation of an organism was considered indicative of 
an IMI. A sample was considered contaminated if >3 
pathogens were cultured from a sample. If this occurred, 
the duplicate sample was submitted for bacteriological 
analysis (Bradley and Green, 2000). Several outcomes 
were assessed as outlined below.
The overall and species-specific cure rate were es-
timated and compared between groups. A cure was 
defined as the absence of a pathogen in the post-calving 
sample that had been present at DO.
The overall and species-specific new infection rates 
were estimated and compared between groups. A new 
infection was defined as the presence of a pathogen in 
the post-calving sample that had not been present at 
DO. Therefore, a quarter infected with 1 pathogen at 
DO was eligible to acquire a new infection with a dif-
ferent pathogen.
Successful dry period outcomes were estimated and 
compared between groups using methods described 
previously (Newton et al., 2008). A successful outcome 
was defined in 2 ways: 1) the absence of a major patho-
gen from the post-calving sample, and 2) the absence 
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of any mastitis pathogen (major or minor) from the 
post-calving sample.
The overall and species-specific incidence rate of 
clinical mastitis was assessed in the first 100 d of lacta-
tion and compared between products.
Data Collation and Statistical Analyses
Data were collated and initially analyzed using Ex-
cel and Access 2003 (Microsoft Corp., Redmond, WA) 
and Minitab 15.1 (Minitab Inc., State College, PA). 
Descriptive and graphical analyses were carried out 
to explore the data. Where appropriate, groups were 
compared using the Kruskal-Wallis test because data 
were not normally distributed. Univariable analysis of 
treatment efficacy was performed using the chi-square 
test to investigate differences in proportions between 
groups. A layered Bonferroni correction was used to 
allow for multiple comparisons where appropriate (Dar-
lington, 1990). Analysis of infected and uninfected cows 
was done separately.
Multilevel logistic regression models were specified 
with the response variables 1) absence of IMI post-
calving (successful outcome) or 2) clinical mastitis on 
1 or more occasions within the first 100 d post-calving. 
Random effects were included for cow (level 2) to ac-
count for correlations within the data (i.e., quarters 
within cows). Potential confounding factors such as 
farm, DIM, milk yield at DO, dry period length, and 
parity were tested and included in final models only if 
they influenced the treatment effect, which in any event 
they did not. The models took the general form
Responseij ~Bernoulli(probability = μij)
logit(μij) = α + β1TXij + β2Xij + β3Xj + vj
vj ~normal distribution (mean = 0,σ
2
v),
where the subscripts i and j = ith quarter and the 
jth cow, respectively; μij = the fitted probability of the 
response in quarter i of cow j; α = regression intercept; 
TXij = covariate treatment; β1 = coefficient for TXij; 
Xij = vector of quarter-level covariates; β2 = coefficients 
for Xij; Xj = vector of cow-level covariates; β3 = coef-
ficients for Xj; vj = random effect reflecting residual 
variation between cows; and σ2v = between-cow vari-
ance. Parameter estimation and assessment of model 
fit were conducted within a recently described Markov 
chain Monte Carlo framework (Browne, 1998; Green et 
al., 2004).
RESULTS
A total of 890 (457 high-SCC infected and 433 low-
SCC uninfected) cows were enrolled between July 2007 
and April 2008 from the 6 farms in the study; details 
of the number of cows recruited from each farm and 
farm management are outlined in Table 1. Data from 
a total of 810 and 839 cows were incorporated into the 
analyses pertaining to dry period IMI and clinical mas-
titis, respectively. Eighty animals were not available for 
inclusion in the analyses for the following reasons: ani-
mals either were not pregnant or calved beyond the end 
of the study (n = 45), animals were not sampled within 
10 d post-calving (n = 21), animals were not allocated 
to the correct treatment group (n = 6), and both of the 
screening samples of animals were contaminated such 
that an assessment of new IMI or cure could not be 
accurately undertaken (n = 8).
The key indices and traits relating to animals in-
cluded in the final analysis of efficacy are shown in 
Table 2. Unsurprisingly, cows categorized as infected 
at DO, compared with cows categorized as uninfected, 
were of higher parity [3 (2–4) vs. 2 (1–3), median and 
interquartile range; P < 0.05], were lower yielding [6 
(5.0–10.4) vs. 9 (6.0–20.1) L; P < 0.05], and had longer 
dry periods [62 (56–72) vs. 59 (54–65) d; P < 0.05].
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Table 1. Key characteristics of the 6 study farms1 
Item
Farm ID
D F G H S T
Approximate herd size, cows in milk (n) 300 200 250 220 150 610
Predominant breed G HF HF HF HF HF
Animals recruited (n) 224 123 137 91 89 226
Geometric mean bulk milk SCC in the 5 mo before the study (×103 cells/mL) 118 172 172 240 163 193
Dry cow winter housing C, Y C, Y C, Y Y C C, Y
Predominant dry cow summer housing P C, Y P P P Y
Predominant dry cow bedding Straw Sand Straw Straw Straw Straw
1G = Guernsey; HF = Holstein-Friesian; C = free stalls; Y = covered straw yards; P = pasture.
Univariable Analysis
Prevalence of Infection. The prevalence of the 
key mastitis pathogens at DO and post-calving in the 
high-SCC infected and low-SCC uninfected categories 
are described in Tables 3 and 4, respectively. When 
comparing within infection category (i.e., infected or 
uninfected), no significant differences in the preva-
lence of infection at DO were identified. There were 
significant differences in the prevalence of pathogens 
present post-calving. Quarters in high-SCC infected 
cows treated with ABTS were less likely infected with 
a major pathogen (112/838 vs. 83/838; P < 0.05) or a 
minor pathogen (270/838 vs. 230/838; P < 0.05) than 
those treated with AB. When the likelihood of being 
free of any pathogen post-calving was considered, the 
ABTS-treated quarters in high-SCC infected cows were 
more likely (506/838 vs. 560/838; P < 0.05) pathogen-
free than those treated with AB. When considering 
quarters treated in low-SCC uninfected cows, quarters 
receiving TSAB treatment were not significantly less 
likely infected compared with quarters treated with 
TS alone, with the exception of the prevalence of IMI 
at calving with coagulase-positive staphylococci and 
Streptococci spp. combined (23/782 vs. 11/782; P < 
0.05). There was a trend for TSAB-treated quarters 
in the low-SCC uninfected group to be more likely to 
be pathogen free post-calving than TS-treated quarters 
(492/782 vs. 526/782; P = 0.07).
Apparent Dry Period Cure Rate. The pathogen-
specific apparent cure rates for the mastitis pathogens 
are shown in Table 5. No significant differences in the 
cure rates were identified for any of the major or minor 
pathogens when each were considered and compared 
between treatment groups within infection categories. 
Cure rates were exceptionally high in all treatment 
groups, with pathogen-specific cure rates consistently 
in excess of 90% for all susceptible species.
Apparent Dry Period New IMI Rate. The 
pathogen-specific apparent new infection rates for the 
key mastitis pathogens are shown in Table 6. No signifi-
cant differences in the new infection rates were identi-
fied for any of the major or minor pathogens when 
each were considered and compared between treatment 
groups within infection categories.
Dry Period Outcomes. Dry period outcomes for 
each of the treatment groups are shown in Table 7. 
When comparing within treatment categories, there 
was no significant difference in the number of quarters 
curing or acquiring an IMI during the dry period. There 
was a significant difference in the number of quarters 
experiencing a successful dry period outcome, defined 
as being pathogen free post-treatment. Combination-
treated quarters in the high-SCC infected cows category 
were more likely to be pathogen free post-calving than 
were quarters treated with AB (500/830 vs. 554/831; P 
< 0.05). There was a trend for TSAB-treated quarters 
in the low-SCC uninfected cows category to be patho-
gen free post-calving compared with quarters treated 
with TS alone (489/777 vs. 523/779; P = 0.08).
Clinical Mastitis. A total of 262 cases of clinical 
mastitis occurred in 227 quarters during the dry period 
and in the first 100 d of the subsequent lactation. For 
the purposes of assessing efficacy, only the first case 
occurring in each quarter was considered. The number 
of cases and etiology of the first case in each quarter 
are shown in Table 8. In the high-SCC infected cow cat-
egory, quarters of ABTS-treated cows were less likely 
to develop clinical mastitis than were quarters of AB-
treated cows (59/862 vs. 84/862; P = 0.03). Combina-
tion-treated quarters were less likely to suffer a case of 
clinical mastitis caused by a major mastitis pathogen 
(30/862 vs. 59/862; P = 0.002) or an enterobacterial 
pathogen (11/862 vs. 24/862; P = 0.03). In the low-
SCC uninfected cow category, there was no significant 
difference in the proportion of quarters suffering a case 
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Table 2. Summary of data from cows (419 infected, 391 uninfected) and quarters (838 infected, 782 uninfected) included in the analysis of 
product efficacy as measured by cure and acquisition of IMI during the dry period1 
Item
Infected Uninfected
Mean Median Minimum Maximum Mean Median Minimum Maximum
Parity 3.32 3a 1 10 2.34 2b 1 13
Dry period length (d) 70 62a 3 306 61 59b 2 167
Milk yield at drying off (L) 9.6 6a 1 41.4 13.7 9b 1 50
Individual cow SCC (×103 cells/mL)
 1 mo before drying off 492 307a 12 6,041 84 75b 6 198
 2 mo before drying off 329 229a 16 7,112 73 64b 5 199
 3 mo before drying off 276 193a 12 4,367 67 54b 1 196
a,bMeans within a row with different superscripts differ (P < 0.05).
1Cows with the last 3 monthly individual SCC <200,000 cells/mL and no clinical mastitis within that period were allocated to the uninfected 
group; all other animals (with complete records) were allocated to the infected group.
of clinical mastitis; however, quarters receiving TSAB 
were more likely to develop clinical mastitis caused by 
E. coli (9/816 vs. 1/816; P = 0.01) or an enterobacte-
rial pathogen (12/816 vs. 1/816; P = 0.002).
Retention of Teat Sealant. A total of 3,176 quar-
ters were sampled post-calving for the purposes of de-
termining the quantity of residual solids; 429 quarters 
were excluded from the analysis because they had been 
suckled before sampling (Table 9). There was variation 
in the residual mass of solids recovered within treatment 
groups, with all groups having quarters from which no 
solids were recovered. The mass of solids recovered from 
individual combination-treated quarters (ABTS and 
TSAB combined) was less than that from individual 
quarters receiving TS (0.16 vs. 0.38 g; P < 0.0001).
Multivariable Analysis
Dry Period Outcomes. Several different outcomes 
were investigated, including the likelihood of a quarter 
being free of a major mastitis pathogen post-calving 
and of being free of any pathogen post-calving (i.e., no 
growth post calving). The potential confounding influ-
ence of the presence of infection at DO was tested in 
all models. The findings of these models are shown in 
Table 10. In the high-SCC infected category, compared 
with AB-treated quarters, ABTS-treated quarters had 
increased odds of being free of a major mastitis patho-
gen post-calving (odds ratio = 1.40; 95% credibility in-
terval = 1.03–1.90) or of no growth post-calving (odds 
ratio = 1.32; 95% credibility interval = 1.08–1.61). No 
significant differences were identified between the treat-
ment groups in the low-SCC uninfected cow category.
Clinical Mastitis. The findings of the models in-
vestigating factors that influence clinical mastitis are 
shown in Table 11. The proportion of quarters develop-
ing clinical mastitis during the dry period and in the 
first 100 d of lactation was compared between treat-
ment groups within each of the treatment categories. 
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Table 3. Prevalence of mastitis pathogens at each of the sampling time points, restricted to quarters and cows eligible for assessment of product 
efficacy (high-SCC infected cows)1 
Item
Drying off Post-calving
AB (no. of 
quarters = 838)
ABTS (no. of 
quarters = 838)
AB (no. of 
quarters = 838)
ABTS (no. of 
quarters = 838)
n % n % n % n %
Streptococcus uberis 29 3.46 33 3.94 21 2.51 14 1.67
Escherichia coli 16 1.91 7 0.84 28 3.34 20 2.39
Aerococcus spp. 14 1.67 20 2.39 14 1.67 10 1.19
Coagulase-positive staphylococci 12 1.43 12 1.43 8 0.95 3 0.36
Enterococcus spp. 8 0.95 7 0.84 11 1.31 4 0.48
Bacillus spp. 4 0.48 6 0.72 1 0.12 3 0.36
Yeast spp. 4 0.48 2 0.24 11 1.31 8 0.95
Unspeciated gram-negative 3 0.36 5 0.60 8 0.95 9 1.07
Streptococcus spp. 3 0.36 5 0.60 0 0.00 1 0.12
Mucor spp. 2 0.24 1 0.12 3 0.36 3 0.36
Streptococcus dysgalactiae 2 0.24 4 0.48 0 0.00 3 0.36
Aspergillus spp. 1 0.12 3 0.36 2 0.24 2 0.24
Pseudomonas spp. 1 0.12 0 0.00 2 0.24 1 0.12
Arcanobacterium pyogenes 0 0.00 0 0.00 1 0.12 0 0.00
All Enterobacteriaceae 22 2.63 14 1.67 38 4.54 24 2.86
Staph./Strep. spp.2 54 6.44 59 7.04 39 4.65 25 2.98
Other major pathogens 2 0.24 2 0.24 2 0.24 3 0.36
All major pathogens3 100 11.93 107 12.77 112 13.37a 83 9.90b
Coagulase-negative staphylococci 268 31.98 257 30.67 213 25.42 178 21.24
Corynebacterium spp. 352 42.00 345 41.17 95 11.34 86 10.26
All minor pathogens3 510 60.86 494 58.95 270 32.22a 230 27.45b
No growth 286 34.13 306 36.52 506 60.38a 560 66.83b
Contaminated 2 0.24 3 0.36 6 0.72 4 0.48
Total3 550 65.63 529 63.13 325 38.78 274 32.70
a,bMeans within a row within sampling time points with different superscripts differ (P < 0.05).
1Cows with the last 3 monthly individual SCC <200,000 cells/mL and no clinical mastitis within that period were allocated to the uninfected 
group; all other animals (with complete records) were allocated to the infected group. AB = antibiotic only treatment in infected cows; ABTS 
= combination treatment in infected cows. 
2Coagulase-positive staphylococci and all Streptococcus species.
3Totals may not equal sum of the individual pathogens as a result of mixed infections.
Combination-treated quarters in the high-SCC infected 
cow category were less likely to develop clinical mastitis 
(odds ratio = 0.68; 95% credibility interval = 0.48–0.98), 
whereas TSAB in the low-SCC uninfected category was 
not significantly different from TS.
DISCUSSION
The data and results outlined demonstrate the efficacy 
of the broad-spectrum, first generation cephalosporin, 
cephalonium, in the treatment and prevention of IMI 
in nonlactating dairy cows. In particular, cephalonium 
was highly effective in the treatment of existing IMI, 
with cure rates consistently in excess of 90% for all 
pathogens. These results support studies conducted in 
similar farms in the United Kingdom (Berry and Hil-
lerton, 2002b; Newton et al., 2008).
Consistent with other research, with respect to control 
of IMI post-calving, ABTS treatment was more effective 
than AB treatment alone (Godden et al., 2003; Berry 
and Hillerton, 2007; Newton et al., 2008). Interestingly, 
in this study in which the effect of combination treat-
ment was studied in cows of differing infection status 
at DO, the benefits of combining antibiotics and an in-
ternal teat sealant in low-SCC uninfected cows was less 
clear. This study failed to demonstrate increased odds 
of being pathogen free post-calving when using TSAB 
compared with using TS alone in low-SCC uninfected 
cows. This does not mean that there is no effect, but 
it may be that any such effect was too small to detect 
given the power.
Dry cow therapy efficacy is more often assessed by 
measuring cure and new IMI rates. Such traditional 
approaches limit the power of such efficacy studies and 
their ability to identify biologically relevant differences 
in treatment outcome. The use of pathogen free status 
at calving or freedom from a major mastitis pathogen 
is a more biologically relevant measure because it 
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Table 4. Prevalence of mastitis pathogens at each of the sampling time points, restricted to quarters and cows eligible for assessment of product 
efficacy (low-SCC uninfected cows)1 
Item
Drying off Post-calving
TS (no. of 
quarters = 782)
TSAB (no. of 
quarters = 782)
TS (no. of 
quarters = 782)
TSAB (no. of 
quarters = 782)
n % n % n % n %
Streptococcus uberis 2 0.26 7 0.90 9 1.15 7 0.90
Escherichia coli 7 0.90 8 1.02 13 1.66 19 2.43
Aerococcus spp. 10 1.28 14 1.79 6 0.77a 15 1.92b
Coagulase-positive staphylococci 1 0.13 3 0.38 5 0.64 2 0.26
Enterococcus spp. 5 0.64 1 0.13 5 0.64 2 0.26
Bacillus spp. 4 0.51 2 0.26 3 0.38 1 0.13
Yeast spp. 0 0.00 1 0.13 6 0.77 8 1.02
Unspeciated gram-negative 4 0.51 3 0.38 11 1.41 6 0.77
Streptococcus spp. 4 0.51 2 0.26 1 0.13 0 0.00
Mucor spp. 0 0.00 0 0.00 1 0.13 1 0.13
Streptococcus dysgalactiae 1 0.13 0 0.00 4 0.51 0 0.00
Aspergillus spp. 0 0.00 0 0.00 2 0.26 5 0.64
Pseudomonas spp. 0 0.00 1 0.13 1 0.13 2 0.26
Arcanobacterium pyogenes 0 0.00 0 0.00 2 0.26 1 0.13
All Enterobacteriaceae 8 1.02 13 1.66 18 2.30 22 2.81
Staph./Strep. spp.2 13 1.66 13 1.66 23 2.94a 11 1.41b
Other major pathogens 5 0.64 8 1.02 8 1.03 2 0.26
All major pathogens3 41 5.24 54 6.91 77 9.85 65 8.31
Coagulase-negative staphylococci 233 29.80 248 31.71 191 24.42 170 21.74
Corynebacterium spp. 218 27.88 210 26.85 100 12.79 91 11.64
All minor pathogens3 367 46.93 370 47.31 255 32.61 224 28.64
No growth 403 51.53 397 50.77 492 62.92 526 67.26
Contaminated 5 0.64 1 0.13 0 0.00 2 0.26
Total3 374 47.83 384 49.10 290 37.08 254 32.48
a,bMeans within a row within sampling time points with different superscripts differ (P < 0.05).
1Cows with the last 3 monthly individual SCC <200,000 cells/mL and no clinical mastitis within that period were allocated to the uninfected 
group; all other animals (with complete records) were allocated to the infected group. TS = internal teat sealant treatment in uninfected cows; 
TSAB = combination treatment in uninfected cows.
2Coagulase-positive staphylococci and all Streptococcus species.
3Totals may not equal sum of the individual pathogens as a result of mixed infections.
combines both aspects of dry cow therapy efficacy and 
allows assessment of the overall variable most likely to 
affect cow health and profitability.
With respect to clinical mastitis, in a similar manner 
to earlier research (Newton et al., 2008), ABTS treat-
ment in high-SCC infected cows was beneficial, with 
a reduction in clinical mastitis in the first 100 d of 
the subsequent lactation. Interestingly, the reduction 
in clinical mastitis was less marked than in a similar 
study conducted when shorter acting, narrow-spectrum 
antibiotic dry cow therapy was used (Newton et al., 
2008), suggesting that there may be benefit in the use 
of broad-spectrum, longer acting dry cow therapies 
when such products are used in the absence of an inter-
nal sealant. Again, the pattern in low-SCC uninfected 
cows was less clear; overall, there was no difference in 
the proportion of quarters affected in the 2 groups. The 
incidence of clinical mastitis caused by E. coli and En-
terobacteriaceae was significantly increased when both 
AB and TS were used in combination. This finding 
supports reports of antibiotic dry cow therapy being a 
risk factor for coliform mastitis at calving (Schukken et 
al., 1989) and suggests that the result of using AB in 
combination with TS in low-SCC uninfected cows was 
to change the etiology of clinical mastitis in the next 
lactation without affecting the overall incidence. Given 
the efficacy of an internal TS in reducing gram-negative 
IMI in the dry period and subsequent clinical mastitis 
(Huxley et al., 2002), it is interesting to note that the 
use of an internal TS in addition to AB in low SCC 
cows did not reduce the apparent increased risk of these 
cows developing coliform mastitis; this is undoubtedly 
an area in need of further research.
There was a significant change in the etiology of IMI 
post-calving, with quarters of low-SCC uninfected cows 
receiving TSAB being significantly less likely to be infected 
with a major staphylococcal or streptococcal pathogen. 
It may be that this change in etiology and reduction in 
minor pathogens influenced the likelihood of clinical en-
terobacterial mastitis in the subsequent lactation (Green 
et al., 2002, 2005; Bradley and Green, 2004).
A secondary measure was the finding with respect 
to recovery of the internal TS. Residual solids were 
reported rather than sealant because visual inspection 
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Table 5. Apparent dry period cure rates of the mastitis pathogens1 
Item
Infected cows Uninfected cows
AB (no. of 
quarters = 830)
ABTS (no. of 
quarters = 831)
TS (no. of 
quarters = 777)
TSAB (no. of 
quarters = 779)
n % n % n % n %
Streptococcus uberis 26 92.9 30 93.8 2 100 7 100
Escherichia coli 15 93.8 7 100 7 100 8 100
Aerococcus spp. 12 92.3 19 95 10 100 14 100
Coagulase-positive staphylococci 11 91.7 12 100 0 — 3 100
Enterococcus spp. 8 100 7 100 5 100 1 100
Bacillus spp. 4 100 6 100 4 100 2 100
Yeast spp. 1 25.0 0 — 0 — 0 —
Unspeciated gram-negative 3 100 5 100 4 100 3 100
Streptococcus spp. 3 100 5 100 4 100 2 100
Mucor spp. 2 100 1 100 0 — 0 —
Streptococcus dysgalactiae 2 100 4 100 0 — 0 —
Aspergillus spp. 1 100 3 100 0 — 0 —
Pseudomonas spp. 1 100 0 — 0 — 1 100
Arcanobacterium pyogenes 0 — 0 — 0 — 0 —
All Enterobacteriaceae 21 95.5 13 92.3 8 100 13 100
Staph./Strep. spp.2 50 92.6 56 94.9 11 84.6 13 100
Other major pathogens 2 100 2 100 5 100 8 100
All major pathogens 91 91.9 101 97.1 41 100 49 100
Coagulase-negative staphylococci 181 68.6 189 74.1 139 59.7 166 66.9
Corynebacterium spp. 307 88.2 310 90.4 175 80.3 180 86.1
All minor pathogens 488 79.8 499 83.5 314 69.7 346 75.7
Total 579 81.4 600 85.5 355 72.2 395 78.0
1Cows with the last 3 monthly individual SCC <200,000 cells/mL and no clinical mastitis within that period were allocated to the uninfected 
group; all other animals (with complete records) were allocated to the infected group. AB = antibiotic only treatment in infected cows; ABTS = 
combination treatment in infected cows; TS = internal teat sealant treatment in uninfected cows; TSAB = combination treatment in uninfected 
cows; n = number of infections at drying off that experienced a dry period cure
2Coagulase-positive staphylococci and all Streptococcus species.
.
identified not only foreign matter but also what may 
have been the carrier gel of the dry cow antibiotic in 
some samples. All treatment groups demonstrated a 
maximum mass of recovered solids, which exceeded 
that administered in the form of sealant; this could 
have been for a variety of reasons. Some quarters in 
the group treated only with AB may have received TS 
in error at DO, or the additional mass could have been 
attributed to foreign bodies or residual gel from the 
antibiotic dry cow formulation. Less TS was recovered 
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Table 6. Apparent dry period new IMI rates for the mastitis pathogens1 
Item
Infected cows Uninfected cows
AB (no. of  
quarters = 830)
ABTS (no. of 
quarters = 831)
TS (no. of 
quarters = 777)
TSAB (no. of 
quarters = 779)
n % n % n % n %
Streptococcus uberis 19 2.35 12 1.49 9 1.15 7 0.90
Escherichia coli 27 3.28 20 2.41 13 1.68 19 2.45
Aerococcus spp. 13 1.58 9 1.10 6 0.78 15 1.95
Coagulase-positive staphylococci 7 0.85 3 0.36 4 0.51 2 0.26
Enterococcus spp. 11 1.33 4 0.48 5 0.64 2 0.26
Bacillus spp. 1 0.12 3 0.36 3 0.39 1 0.13
Yeast spp. 8 0.96 6 0.72 6 0.77 7 0.90
Unspeciated gram-negative 8 0.96 9 1.08 11 1.41 6 0.77
Streptococcus spp. 0 0.00 1 0.12 1 0.13 0 0.00
Mucor spp. 3 0.36 3 0.36 1 0.13 1 0.13
Streptococcus dysgalactiae 0 0.00 3 0.36 3 0.38 0 0.00
Aspergillus spp. 2 0.24 2 0.24 2 0.26 5 0.64
Pseudomonas spp. 2 0.24 1 0.12 1 0.13 2 0.26
Arcanobacterium pyogenes 1 0.12 0 0.00 2 0.26 1 0.13
All Enterobacteriaceae 37 4.53 24 2.91 18 2.33 22 2.86
Staph./Strep. spp.2 34 4.34 23 2.95 21 2.73 11 1.43
Other major pathogens 2 0.24 3 0.36 8 1.10 2 0.26
All major pathogens3 104 79 75 70
Coagulase-negative staphylococci 128 22.54 112 19.28 95 17.37 88 16.48
Corynebacterium spp. 54 11.11 52 10.57 56 9.95 62 10.84
All minor pathogens3 182 164 151 150
Total3 286 243 226 220
1Cows with the last 3 monthly individual SCC <200,000 cells/mL and no clinical mastitis within that period were allocated to the uninfected 
group; all other animals (with complete records) were allocated to the infected group. AB = antibiotic only treatment in infected cows; ABTS = 
combination treatment in infected cows; TS = internal teat sealant treatment in uninfected cows; TSAB = combination treatment in uninfected 
cows; n = number of new infections acquired.
2Coagulase-positive staphylococci and all Streptococcus species.
3Total number of IMI including mixed infections.
Table 7. Summary of the quarter-level dry period outcomes for each of the treatment groups1,2 
Item 
Infected cows Uninfected cows
AB ABTS TS TSAB
Quarters treated (n) 830 831 777 779
Quarters infected at drying off (n) 546 529 379 384
Quarters uninfected at drying off (n) 284 302 398 395
Quarters uninfected post-calving (n) 500a 554b 489 523
Quarters experiencing a dry period cure (n) 189 206 293 290
Quarters becoming infected during the dry period (n) 95 96 105 105
a,bMeans within a row within treatment categories with different superscripts differ (P < 0.05).
1Values may differ from those in Tables 3, 4, 5, and 6 as a result of exclusion of data from quarters in which a 
sample was contaminated either at drying off or post-calving. 
2Cows with the last 3 monthly individual SCC <200,000 cells/mL and no clinical mastitis within that period 
were allocated to the uninfected group; all other animals (with complete records) were allocated to the infected 
group. AB = antibiotic only treatment in infected cows; ABTS = combination treatment in infected cows; TS 
= internal teat sealant treatment in uninfected cows; TSAB = combination treatment in uninfected cows.
post-calving from quarters treated with the TS in com-
bination with an oil-based antibiotic formulation than 
from quarters treated with TS alone. Although this did 
not affect efficacy as measured, it does raise questions 
about the suitability of the current formulation when 
used in combination with oil-based antibiotics. It is 
likely that the 2 products were miscible and may, if ap-
plied in combination, result in a change in the viscosity 
of the TS, which may affect its ability to function as 
a plug. The reduction in the amount of TS recovered 
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Table 8. Summary of first-quarter cases of clinical mastitis occurring in quarters eligible for inclusion in the analysis of efficacy as measured 
by the occurrence of clinical mastitis1 
Item (n)
Infected cows Uninfected cows
AB (no. of 
quarters = 862)
ABTS (no. of 
quarters = 862)
TS (no. of 
quarters = 816)
TSAB (no. of 
quarters = 816)
Escherichia coli 17 9 1a 9b
Streptococcus uberis 11 6 4 3
Coagulase-positive staphylococci 5 2 1  
Klebsiella spp. 3 1  2
Yeast spp. 3 2  3
Arcanobacterium pyogenes 2    
Lactococcus spp. 2    
Streptococcus dysgalactiae 2 1  2
Serratia spp. 2 1  1
Unspeciated gram-negative 2  1  
Enterobacter spp. 1    
Enterococcus spp. 1 2  2
Proteus spp. 1    
Pseudomonas spp. 1    
Aspergillus spp.  1   
Bacillus spp.  1   
Streptococcus spp.   1  
All Enterobacteriaceae 24a 11b 1a 12b
Mixed infection 6 4 3 5
All major pathogens 59a 30b 11 27
Coagulase-negative staphylococci 3 5 3 5
Corynebacterium spp. 1 2 1  
Coagulase-negative staphylococci and Corynebacterium spp.  2   
All minor pathogens 4 9 4 5
No growth 10 10 11 4
No sample 10 10 14 8
Contaminated 1  1  
Total 84a 59b 41 44
a,bMeans within a row within treatment categories with different superscripts differ (P < 0.05).
1Cows with the last 3 monthly individual SCC <200,000 cells/mL and no clinical mastitis within that period were allocated to the uninfected 
group; all other animals (with complete records) were allocated to the infected group. AB = antibiotic only treatment in infected cows; ABTS = 
combination treatment in infected cows; TS = internal teat sealant treatment in uninfected cows; TSAB = combination treatment in uninfected 
cows.
Table 9. Summary of the quantity of residual solids recovered from quarters in each of the treatment groups 
when sampled immediately post-calving 
Treatment group1 n Mean (g) Median (g) Minimum (g) Maximum (g)
AB 716 0.17 0.05a 0.00 5.36
ABTS 720 0.65 0.14b 0.00 6.33
TS 659 1.27 0.38c 0.00 6.34
TSAB 652 0.78 0.20b 0.00 5.24
a–cMeans within a column with different superscripts differ (P < 0.05).
1Cows with the last 3 monthly individual SCC <200,000 cells/mL and no clinical mastitis within that period 
were allocated to the uninfected group; all other animals (with complete records) were allocated to the infected 
group. AB = antibiotic only treatment in infected cows; ABTS = combination treatment in infected cows; TS 
= internal teat sealant treatment in uninfected cows; TSAB = combination treatment in uninfected cows.
could have been a result of loss of the product from the 
gland or a result of increased dispersal post-infusion; 
either or a combination of the 2 are biologically plau-
sible. The apparent effect on retention of the TS when 
used in combination with an oil-based dry cow therapy 
questions the compatibility of such products; it may 
be that the use of a water-based antibiotic formulation 
in combination with the internal TS would be more 
appropriate.
This study presents several conundrums to the 
practitioner. It reinforces the need for careful selection 
and targeting of dry cow therapies and demonstrates 
the need for both AB and nonantibiotic approaches. 
It appears to support the need to stratify herds ac-
cording to mastitis etiology and pathogen prevalence 
as well as cows on the basis of likely infection status. 
The data suggest that in herds with a high prevalence 
of gram-positive pathogens (and high BMSCC) liberal 
use of AB in both low- and high-SCC cows may be 
justified because the imperative is to decrease the over-
all prevalence of infection. Conversely, in herds with 
a low prevalence of gram-positive infection (and low 
BMSCC) the priority may be to optimize control of 
gram-negative infection and minimize the use of AB in 
low-SCC cows. Although this approach may be optimal, 
it is important to consider the technical ability of farm 
personnel because the use of internal TS alone demands 
the highest level of aseptic technique.
CONCLUSIONS
The decision of whether to treat cows with both an-
tibiotic dry cow therapy and an internal TS appears 
complex. Whereas significant benefits are associated 
with ABTS in high-SCC infected cows at DO, the 
benefits of TSAB in low-SCC uninfected cows appear 
less clear. This research suggests that the decision to 
combination-treat low-SCC uninfected cows is not 
straightforward and needs to be tempered by the preva-
lence of different pathogens within the herd as well as 
the need to manage the current level of BMSCC.
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Table 10. Summary of the findings for the multilevel models relating to post-calving outcomes for the infected and uninfected cow categories1 
Outcome Intercept
Treatment 
group
Treatment 
coefficient SE
Treatment 
odds ratio
95% credibility interval
Lower Upper
High-SCC infected cows (reference category = AB)
 No growth post-calving 0.507 ABTS 0.277 0.10 1.32 1.08 1.61
 Free of a major pathogen post-calving −2.02 ABTS 0.334 0.15 1.40 1.03 1.90
Low-SCC uninfected cows (reference category = TS)
 No growth post-calving 0.529 TSAB 0.167 0.10 1.18 0.96 1.45
 Free of a major pathogen post-calving −2.14 TSAB −0.149 0.17 0.86 0.61 1.22
1Cows with the last 3 monthly individual SCC <200,000 cells/mL and no clinical mastitis within that period were allocated to the uninfected 
group; all other animals (with complete records) were allocated to the infected group. AB = antibiotic only treatment in infected cows; ABTS = 
combination treatment in infected cows; TS = internal teat sealant treatment in uninfected cows; TSAB = combination treatment in uninfected 
cows.
Table 11. Summary of the findings for the multilevel models relating to clinical mastitis outcomes for each of the cow categories1 
Outcome Intercept
Treatment 
group
Treatment 
coefficient SE
Treatment 
odds ratio
95% credibility interval
Lower Upper
High-SCC infected cows (reference category = AB)
 Clinical mastitis −2.37 ABTS −0.381 0.18 0.68 0.48 0.98
Low-SCC uninfected cows (reference category = TS)
 Clinical mastitis −0.356 TSAB −0.116 0.18 0.89 0.62 1.28
1Cows with the last 3 monthly individual SCC <200,000 cells/mL and no clinical mastitis within that period were allocated to the uninfected 
group; all other animals (with complete records) were allocated to the infected group. AB = antibiotic only treatment in infected cows; ABTS = 
combination treatment in infected cows; TS = internal teat sealant treatment in uninfected cows; TSAB = combination treatment in uninfected 
cows.
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